Inovio Pharmaceuticals Inc (NASDAQ:INO) has addressed the manufacturing issue for INO 3,107, aiming for FDA acceptance by the end of 2025. Clinical data shows benefits, but financial challenges persist with a significant net loss in 2024.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing